Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® ...

US FDA accepts Roche’s Gazyva/Gazyvaro sBLA for the treatment of lupus nephritis: Basel Thursday, March 6, 2025, 09:00 Hrs [IST] Roche announced that the US Food and Drug Admini ...

A startup called Marine Biologics is breaking down seaweed into its base components so they can be used for a range of consumer applications, from foodstuffs to cosmetics to bioplastics.

Trestle Biotherapeutics, Inc., today announced a research collaboration with Humacyte, Inc. (Nasdaq: HUMA), a ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Ocugen Inc (OCGN) outlines pivotal trial progress and financial strategies while navigating increased expenses and market ...

Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are ...

Ocugen, Inc.'s stock dropped 2.8% during Wednesday's session but bounced back in extended trading after the company posted a ...

The sequence contained a promising new genetic tool for modifying DNA, a CRISPR. Editas Medicine, a Massachusetts-based ...

Q4 2024 Earnings Call Transcript March 5, 2025 Zymeworks Inc. misses on earnings expectations. Reported EPS is $-0.31 EPS, ...

A recently launched Phase 1 clinical trial at Mass General Brigham is examining the safety and feasibility of a groundbreaking treatment approach for ...

VisionWave Technologies Coming to Market via Merger with Bannix Acquisition Corp.Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp.